| Bioactivity | Ditiocarb (Diethyldithiocarbamic acid) is an accelerator of the rate of copper cementation. Ditiocarb (Diethyldithiocarbamic acid) reduces the incidence of HIV infection, and also enhances adjuvant immunotherapy of high risk breast cancer[1][2][3]. |
| Invitro | Ditiocarb与 Cu2+ 溶液反应生成二乙基二硫代氨基甲酸铜配合物，提高了的胶结速率[1]。Ditiocarb 是一种具有较强抗氧化能力和螯合活性的化合物[2]。 |
| In Vivo | Ditiocarb 改善新生和老年小鼠的免疫反应。Ditiocarb 在不降低抗肿瘤活性的情况下可预防顺铂对动物的肾毒性。在艾滋病模型中，Ditiocarb 减少淋巴结病和高 γ 球蛋白血症，恢复免疫能力，延长生存[2]。 |
| Name | Ditiocarb |
| CAS | 147-84-2 |
| Formula | C5H11NS2 |
| Molar Mass | 149.28 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Abeer A.El-Saharty, et al. Sodium diethyldithiocarbamate as accelerator of the rate of copper cementation. The Egyptian Journal of Aquatic Research. 2015 Dec, Volume 41(4):289-293. [2]. Hersh EM, et al. Ditiocarb sodium (diethyldithiocarbamate) therapy in patients with symptomatic HIV infection and AIDS. A randomized, double-blind, placebo-controlled, multicenter study. JAMA. 1991 Mar 27;265(12):1538-44. [3]. Dufour P, et al. Sodium dithiocarb as adjuvant immunotherapy for high risk breast cancer: a randomized study. Biotherapy. 1993;6(1):9-12. |